Publications

Jump below to

2011–Now​​

  1. Garcia-Cremades M, Solans BP, Strydom N, Vrijens B, Pillai GC, Shaffer C, Thomas B, Savic RM. Emerging Therapeutics, Technologies, and Drug Development Strategies to Address Patient Nonadherence and Improve Tuberculosis Treatment. Annu Rev Pharmacol Toxicol. 2021 Sep 30. doi: 10.1146/annurev-pharmtox-041921-074800. Epub ahead of print. PMID: 34591605.

    View in: PubMed

  2. Musisi E, Dide-Agossou C, Al Mubarak R, Rossmassler K, Ssesolo AW, Kaswabuli S, Byanyima P, Sanyu I, Zawedde J, Worodria W, Voskuil MI, Savic RM, Nahid P, Davis JL, Huang L, Moore CM, Walter ND. Reproducibility of the Ribosomal RNA Synthesis Ratio in Sputum and Association with Markers of Mycobacterium tuberculosis Burden. Microbiol Spectr. 2021 Sep 8:e0048121. doi: 10.1128/Spectrum.00481-21. Epub ahead of print. PMID: 34494858.

    View in: PubMed

  3. Verma R, Patil S, Zhang N, Moreira FMF, Vitorio MT, Santos ADS, Wallace E, Gnanashanmugam D, Persing D, Savic R, Croda J, Andrews JR. A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment. Am J Respir Crit Care Med. 2021 Aug 10. doi: 10.1164/rccm.202103-0564OC. Epub ahead of print. PMID: 34375564.

    View in: PubMed

  4. Imperial MZ, Phillips PPJ, Nahid P, Savic RM. Precision-enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials. Am J Respir Crit Care Med. 2021 Aug 4. doi: 10.1164/rccm.202101-0117OC. Epub ahead of print. PMID: 34346856.

    View in: PubMed

  5. Hills NK, Lyimo J, Nahid P, Savic RM, Lienhardt C, Phillips PPJ. A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials. Trials. 2021 Aug 3;22(1):515. doi: 10.1186/s13063-021-05388-1. PMID: 34344435; PMCID: PMC8329622.

    View in: PubMed

  6. Mathad JS, Savic R, Britto P, Jayachandran P, Wiesner L, Montepiedra G, Norman J, Zhang N, Townley E, Chakhtoura N, Bradford S, Patil S, Popson S, Chipato T, Rouzier V, Langat D, Chalermchockcharoentkit A, Kamthunzi P, Gupta A, Dooley KE; IMPAACT 2001 Study Team. Pharmacokinetics and Safety of Three Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. Clin Infect Dis. 2021 Jul 29:ciab665. doi: 10.1093/cid/ciab665. Epub ahead of print. PMID: 34323955.

    View in: PubMed

  7. Radtke KK, Hesseling AC, Winckler JL, Draper HR, Solans BP, Thee S, Wiesner L, van der Laan LE, Fourie B, Nielsen J, Schaaf HS, Savic RM, Garcia-Prats AJ. Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children. Clin Infect Dis. 2021 Jul 21:ciab641. doi: 10.1093/cid/ciab641. Epub ahead of print. PMID: 34286843

    View in: PubMed

  8. Gewitz AD, Solans BP, Mac Kenzie WR, Heilig C, Whitworth WC, Johnson JL, Nsubuga P, Dorman S, Weiner M, Savic RM; Tuberculosis Trials Consortium of the Centers for Disease Control Prevention. A Longitudinal Model-Based Biomarker Analysis of Exposure Response in Adults with Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2021 Jul 12:AAC0179420. doi: 10.1128/AAC.01794-20. Epub ahead of print. PMID: 3425230

    View in: PubMed

  9. Ernest JP, Sarathy J, Wang N, Kaya F, Zimmerman MD, Strydom N, Wang H, Xie M, Gengenbacher M, Via LE, Barry CE 3rd, Carter CL, Savic RM, Dartois V. Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis. Antimicrob Agents Chemother. 2021 Jul 12:AAC0050621. doi: 10.1128/AAC.00506-21. Epub ahead of print. PMID: 34252307.

    View in: PubMed

  10. Walter ND, Born SEM, Robertson GT, Reichlen M, Dide-Agossou C, Ektnitphong VA, Rossmassler K, Ramey ME, Bauman AA, Ozols V, Bearrows SC, Schoolnik G, Dolganov G, Garcia B, Musisi E, Worodria W, Huang L, Davis JL, Nguyen NV, Nguyen HV, Nguyen ATV, Phan H, Wilusz C, Podell BK, Sanoussi ND, de Jong BC, Merle CS, Affolabi D, McIlleron H, Garcia-Cremades M, Maidji E, Eshun-Wilson F, Aguilar-Rodriguez B, Karthikeyan D, Mdluli K, Bansbach C, Lenaerts AJ, Savic RM, Nahid P, Vásquez JJ, Voskuil MI. Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens. Nat Commun. 2021 May 18;12(1):2899. doi: 10.1038/s41467-021-22833-6. PMID: 34006838; PMCID: PMC8131613.

    View in: PubMed

  11. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. PMID: 33951360.

    View in: PubMed

  12. Vora B, Brackman DJ, Zou L, Garcia-Cremades M, Sirota M, Savic RM, Giacomini KM. Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics. Clin Transl Sci. 2021 Jul;14(4):1431-1443. doi: 10.1111/cts.12992. Epub 2021 May 1. PMID: 33931953; PMCID: PMC8301548.

    View in: PubMed

  13. Jayachandran P, Knox SJ, Garcia-Cremades M, Savić RM. Clinical Pharmacokinetics of Oral Sodium Selenite and Dosing Implications in the Treatment of Patients with Metastatic Cancer. Drugs R D. 2021 Jun;21(2):169-178. doi: 10.1007/s40268-021-00340-9. Epub 2021 Apr 17. PMID: 33866531; PMCID: PMC8206290.

    View in: PubMed

  14. Hughes E, Wallender E, Mohamed Ali A, Jagannathan P, Savic RM. Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations. Clin Pharmacol Ther. 2021 Mar 24. doi: 10.1002/cpt.2238. Epub ahead of print. PMID: 33763871.

    View in: PubMed

  15. Ordonez AA, Tucker EW, Anderson CJ, Carter CL, Ganatra S, Kaushal D, Kramnik I, Lin PL, Madigan CA, Mendez S, Rao J, Savic RM, Tobin DM, Walzl G, Wilkinson RJ, Lacourciere KA, Via LE, Jain SK. Visualizing the dynamics of tuberculosis pathology using molecular imaging. J Clin Invest. 2021 Mar 1;131(5):e145107. doi: 10.1172/JCI145107. PMID: 33645551; PMCID: PMC7919721.

    View in: PubMed

  16. Jayachandran P, Garcia‐Cremades M, Vučićević K, Bumpus NN, Anton P, Hendrix C, Savic R. A Mechanistic In Vivo/Ex Vivo Pharmacokinetic‐Pharmacodynamic Model of Tenofovir for HIV Prevention. CPT: Pharmacometrics & Systems Pharmacology. 2021 Feb. 6. doi: 10.1002/psp4.12583. PMID: 33547874

    View in: PubMed 

  17. Kang WH, Lee JY, Chae JW, Lee KR, Baek IH, Kim MS, Back HM, Jung S, Shaffer C, Savic R, Yun HY. Population Pharmacokinetic Method to Predict Within-Subject Variability Using Single-Period Clinical Data. Pharmaceuticals (Basel). 2021 Feb 3;14(2):114. doi: 10.3390/ph14020114. PMID: 33546114.

    View in: PubMed

  18. Zhang N, Savic RM, Boeree MJ, Peloquin C, Weiner M, Heinrich N, Bliven-Sizemore E, Phillips PP, Hoelscher M, Whitworth W, Morlock G, Posey J, Stout JE, Mac Kenzie W, Aarnoutse R, Dooley KE. Optimising pyrazinamide for the treatment of tuberculosis. Eur Respir J. 2021 Feb 4:20020103. doi: 10.1183/13993003.02013-2020. PMID: 33542052

    View in: PubMed

  19. Ernest JP, Strydom N, Wang Q, Zhang N, Nuermberger E, Dartois V, Savic RM. Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:495-516. doi: 10.1146/annurev-pharmtox-030920-011143. Epub 2020 Aug 17. PMID: 32806997; PMCID: PMC7790895.

    View in: PubMed

  20. Radtke KK, Hibma JE, Hesseling AC, Savic RM. Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children. Eur Respir J. 2021 Jan 5;57(1):2001756. doi: 10.1183/13993003.01756-2020. PMID: 32703775; PMCID: PMC7870317.

    View in: PubMed

  21. Hughes E, Imperial M, Wallender E, Kajubi R, Huang L, Jagannathan P, Zhang N, Kakuru A, Natureeba P, Mwima MW, Muhindo M, Mwebaza N, Clark TD, Opira B, Nakalembe M, Havlir D, Kamya M, Rosenthal PJ, Dorsey G, Aweeka F, Savic RM. Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan Women. Antimicrob Agents Chemother. 2020 Nov 17;64(12):e01013-20. doi: 10.1128/AAC.01013-20. PMID: 33020153; PMCID: PMC7674024

View in: PubMed

  1. Fors J, Strydom N, Fox WS, Keizer RJ, Savic RM. Mathematical model and tool to explore shorter multi-drug therapy options for active pulmonary tuberculosis. PLoS Comput Biol. 2020 Aug 18; 16(8):e1008107. PMID: 32810158. PMCID: PMC7480878

    View in: PubMed

  2. Nicol MR, Joshi A, Rizk ML, Sabato PE, Savic RM, Wesche D, Zheng JH, Cook J. Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. Clin Pharmacol Ther. 2020 Dec;108(6):1135-1149. doi: 10.1002/cpt.1993. Epub 2020 Sep 1. PMID: 32687630; PMCID: PMC7404755.

    View in: PubMed

  3. Garcia-Prats AJ, Salazar-Austin N, Conway JH, Radtke K, LaCourse SM, Maleche-Obimbo E, Hesseling AC, Savic RM, Nachman S. COVID-19 pharmacologic treatments for children: research priorities and approach to pediatric studies. Clin Infect Dis. 2020 Jun 29. PMCID: PMCPMC7337679.

    View in: PubMed

  4. Hibma JE, Radtke KK, Dorman SE, Jindani A, Dooley KE, Weiner M, McIlleron HM, Savic RM. Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection. Am J Respir Crit Care Med. 2020 May 15. doi: 10.1164/rccm.201912-2489OC. PMID: 32412342.

View in: PubMed

  1. Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Savic RM. Response to "Quantitative clinical pharmacology input to SARS-CoV-2 therapeutics should be based on robust data." Clin Pharmacol Ther. 2020 Apr 29. PMID: 32348544.

    View in: PubMed

  2. Dooley KE, Savic R, Gupte A, Marzinke MA, Zhang N, Edward VA, Wolf L, Sebe M, Likoti M, Fyvie MJ, Shibambo I, Beattie T, Chaisson RE, Churchyard GJ; DOLPHIN Study Team. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. Lancet HIV. 2020 Jun;7(6):e401-e409. doi: 10.1016/S2352-3018(20)30032-1. Epub 2020 Mar 30. PMID: 32240629.

    View in: PubMed

  3. Lee SA, Telwatte S, Hatano H, Kashuba ADM, Cottrell ML, Hoh R, Liegler TJ, Stephenson S, Somsouk M, Hunt PW, Deeks SG, Yukl S, Savic RM. Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay. J Acquir Immune Defic Syndr. 2020 Apr 15;83(5):530-537. PMID: 32168200.

    View in: PubMed

  4. Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka F, Luetkemeyer A, Savic RM. Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing. Clin Pharmacol Ther. 2020 Apr 14. PMID:32285930.

    View in: PubMed

  5. Zhang N, Strydom N, Tyagi S, Soni H, Tasneen R, Nuermberger EL, Savic RM. Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies. Antimicrob Agents Chemother. 2020 Feb 21;64(3). pii: e01727-19. doi: 10.1128/AAC.01727-19. Print 2020 Feb 21. PMCID: PMC7038312.

    View in: PubMed

  6. Walsh KF, McAulay K, Lee MH, Vilbrun SC, Mathurin L, Francois DJ, Zimmerman M, Kaya F, Zhang N, Saito K, Ocheretina O, Savic R, Dartois V, Johnson WD, Pape JW, Nathan C, Fitzgerald DW. Early bactericidal activity trial of nitazoxanide for pulmonary tuberculosis. Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.01956-19. PMID:32071052.

    View in: PubMed

  7. Bigelow KM, Deitchman AN, Li SY, Barnes-Boyle K, Tyagi S, Soni H, Dooley KE, Savic R, Nuermberger EL. Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis. J Infect Dis. 2020 Jan 29. pii: jiaa016. PMID:31993638.

    View in: PubMed

  8. Vernon A, Fielding K, Savic RM, Dodd L, Nahid P. The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and progmatic trails. PLoS Med. 2019 Dec 10;16(12) :e1002884. PMID:31821323.

    View in: PubMed

  9. Knox SJ, Jayachandran P, Keeling CA, Stevens KJ, Sandhu N, Stamps-DeAnda SL, Savic R, Shura L, Buyyounouski MK, Grimes K. Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer. Transl Oncol. 2019 Nov;12(11):1525-1531. PMCID: PMC6717060.

    View in: PubMed

  10. Dooley KE, Hanna D, Mave V, Eisenach K, Savic RM. Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology. PLoS Med. 2019 Jul 5;16(7):e1002842. PMCID: PMC6611566.

    View in: PubMed

  11. Garcia-Prats AJ, Schaaf HS, Draper HR, Garcia-Cremades M, Winckler J, Wiesner L, Hesseling AC, Savic RM. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies. PLoS Med. 2019 Apr 30;16(4):e1002789. PMCID: PMC6490911.

    View in: PubMed

  12. Strydom N, Gupta SV, Fox WS, Via LE, Bang H, Lee M, Eum S, Shim T, Barry CE 3rd, Zimmerman M, Dartois V, Savic RM. Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization. PLoS Med. 2019 Apr 2;16(4):e1002773. PMID:30939136.

    View in: PubMed

  13. Sarathy J, Blanc L, Alvarez-Cabrera N, O'Brien P, Dias-Freedman I, Mina M, Zimmerman M, Kaya F, Ho Liang HP, Prideaux B, Dietzold J, Salgame P, Savic RM, Linderman J, Kirschner D, Pienaar E, Dartois V. Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. Antimicrob Agents Chemother. 2019 May; 63(5). PMID: 30803965. PMCID: PMC6496041.

    View in: PubMed

  14. Wallender E, Zhang N, Conrad M, Kakuru A, Muhindo M, Tumwebaze P, Kajubi R, Mota D, Legac J, Jagannathan P, Havlir D, Kamya M, Dorsey G, Aweeka F, Rosenthal PJ, Savic RM. Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda. Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01393-18. PMCID:PMC6355581.

    View in: PubMed

  15. Blanc L, Daudelin IB, Podell BK, Chen PY, Zimmerman M, Martinot AJ, Savic RM, Prideaux B, Dartois V. High-resolution mapping of fluoroquinolones in TB rabbit lesions reveals specific distribution in immune cell types. Elife. 2018 Nov 14;7. pii: e41115. PMCID:PMC6249001.

    View in: PubMed

  16. Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018 Nov;24(11):1708-1715. PMID:30397355.

    View in: PubMed

  17. Radtke KK, Dooley KE, Dodd PJ, Garcia-Prats AJ, McKenna L, Hesseling AC, Savic RM. Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study. Lancet Child Adolesc Health. 2019 Jul 16. PMID:31324596.

    View in: PubMed

  18. Lee SA, Elliott JH, McMahon J, Hartogenesis W, Bumpus NN, Lifson JD, Gorelick RJ, Bacchetti P, Deeks SG, Lewin SR, Savic RM. Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. Clin Pharmacol Ther. 2019 Mar;105(3):692-702. PMCID:PMC6379104.

    View in: PubMed

  19. Blanc L, Sarathy JP, Alvarez Cabrera N, O'Brien P, Dias-Freedman I, Mina M, Sacchettini J, Savic RM, Gengenbacher M, Podell BK, Prideaux B, Ioerger T, Dick T, Dartois V. Impact of immunopathology on the antituberculous activity of pyrazinamide. J Exp Med. 2018 Aug 6;215(8):1975-1986. PMCID:PMC6080910.

    View in: PubMed

  20. Rifat D, Prideaux B, Savic RM, Urbanowski ME, Parsons TL, Luna B, Marzinke MA, Ordonez AA, DeMarco VP, Jain SK, Dartois V, Bishai WR, Dooley KE. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. Sci Transl Med. 2018 Apr 4;10(435). pii: eaai7786. PMCID:PMC5969904.

    View in: PubMed

  21. Wallender E, Vucicevic K, Jagannathan P, Huang L, Natureeba P, Kakuru A, Muhindo M, Nakelembe M, Havlir D, Kamya M, Aweeka F, Dorsey G, Rosenthal PJ, Savic RM. Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. J Infect Dis. 2018 Mar 5;217(6):964-972. doi: 10.1093/infdis/jix660. PMCID:PMC5853566.

    View in: PubMed

  22. Savic RM, Jagannathan P, Kajubi R, Huang L, Zhang N, Were M, Kakuru A, Muhindo MK, Mwebaza N, Wallender E, Clark TD, Opira B, Kamya M, Havlir DV, Rosenthal PJ, Dorsey G, Aweeka FT. Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Clin Infect Dis. 2018 Sep 14;67(7):1079-1088. PMCID:PMC6137112

    View in: PubMed

  23. Guiastrennec B, Ramachandran G, Karlsson MO, Kumar AKH, Bhavani PK, Gangadevi NP, Swaminathan S, Gupta A, Dooley KE, Savic RM. Suboptimal Anti-Tuberculosis Drug Concentrations and Outcomes in Small and HIV Coinfected Children in India: Recommendations for Dose Modifications. Clin Pharmacol Ther. 2017 Dec 16. doi: 10.1002/cpt.987. [Epub ahead of print]. PMCID:PMC6004234.

    View in: PubMed

  24. Savic RM, Novakovic AM, Ekblom M, Munafo A, Karlsson MO. Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis.Clin Pharmacokinet. 2017 Oct;56(10):1245-1253. PMCID: PMC5591805.

    View in: PubMed

  25. Wilkinson R, Rohlwink U, Misra U, Crevel R, Mai N, Dooley K, Caws M, Figaji A, Savic RM, Solomons R, Thwaites G. Tuberculous Meningitis. NRNeurol. 2017 Oct;13(10):581-598. PMID:28884751.

    View in: PubMed

  26. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11;19(1):107. PMCID:PMC5594551.

    View in: PubMed

  27. Alsultan A, Savic R, Dooley KE, Weiner M, Whitworth W, Mac Kenzie WR, Peloquin CA; Tuberculosis Trials Consortium. Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis. Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02625-16. PMCID:PMC5444154.

    View in: PubMed

  28. Bartelink IH, Zhang N, Keizer RJ, Strydom N, Converse PJ, Dooley KE, Nuermberger EL, Savic RM. New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response. Clin Transl Sci. 2017 Sep;10(5):366-379. PMCID:PMC5593171.

    View in: PubMed

  29. Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE; Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention. Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials. Clin Pharmacol Ther. 2017 Aug;102(2):321-331. PMCID:PMC5545752.

    View in: PubMed

  30. Rizk ML, Zou L, Savic RM, Dooley KE. Importance of Drug Pharmacokinetics at the Site of Action. Clin Transl Sci. 2017 May;10(3):133-142. PMCID:PMC5421734.

    View in: PubMed

  31. Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Théorêt Y, Duval M, Keizer RJ, Bittencourt H, Hassan M, Güngör T, Wynn RF, Veys P, Cuvelier GD, Marktel S, Chiesa R, Cowan MJ, Slatter MA, Stricherz MK, Jennissen C, Long-Boyle JR, Boelens JJ. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016 Nov; 3(11):e526-e536. PMID: 27746112.

    View in: PubMed

  32. Goswami S, Yee SW, Xu F, Sridhar SB, Mosley JJ, Takahashi A, Kubo M, Maeda S, Davis RL, Roden DM, Hedderson MM, Giacomini KM, Savic R, et al. A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin. Clin Pharmacol Ther. 2016 Jul 14. PMID: 27415606.

    View in: PubMed

  33. Jayakumar A, Savic RM, Everett CK, Benator D, Alland D, Heilig CM, Weiner M, Friedrich SO, Martinson NA, Kerrigan A, Zamudio C, Goldberg SV, Whitworth WC, Davis JL, Nahid P. Xpert MTB/RIF Assay shows faster clearance of M. tuberculosis DNA with higher rifapentine exposure. J Clin Microbiol. 2016 Oct 12. PMID: 27733634.

    View in: PubMed

  34. Bahr NC, Marais S, Caws M, van Crevel R, Wilkinson RJ, Tyagi JS, Thwaites GE, Boulware DR. GeneXpert MTB/Rif to Diagnose Tuberculous Meningitis: Perhaps the First Test but not the Last. Clin Infect Dis. 2016 May 1; 62(9):1133-5. PMID: 26966284; PMCID: PMC4826457 [Available on 05/01/17].

    View in: PubMed, PubMed Central

  35. Nguyen TH, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, John J, Karlsson MO, Mould DR, Pérez Ruixo JJ, Plan EL, Savic R, van Hasselt JG, Weber B, Zhou C, Comets E, Mentré F. Model evaluation of continuous data pharmacometric models: Metrics and graphics. CPT Pharmacometrics Syst Pharmacol. 2016 Nov 24. PMID: 27884052.

    View in: PubMed

  36. Conde MB, Mello FC, Duarte RS, Cavalcante SC, Rolla V, Dalcolmo M, Loredo C, Durovni B, Armstrong DT, Efron A, Barnes GL, Marzinke MA, Savic R, Dooley KE, Cohn S, Moulton LH, Chaisson RE, Dorman SE. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. PLoS One. 2016; 11(5):e0154778. PMID: 27159505; PMCID: PMC4861335.

    View in: PubMed, PubMed Central

  37. Larsen MS, Keizer R, Munro G, Mørk A, Holm R, Savic R, Kreilgaard M. Pharmacokinetic/Pharmacodynamic Relationship of Gabapentin in a CFA-induced Inflammatory Hyperalgesia Rat Model. Pharm Res. 2016 May; 33(5):1133-43. PMID: 26780452.

    View in: PubMed

  38. Hibma JE, Zur AA, Castro RA, Wittwer MB, Keizer RJ, Yee SW, Goswami S, Stocker SL, Zhang X, Huang Y, Brett CM, Savic R, Giacomini KM. The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. Clin Pharmacokinet. 2016 Jun; 55(6):711-21. PMID: 26597253.

    View in: PubMed

  39. Gupta A, Mathad JS, Abdel-Rahman SM, Albano JD, Botgros R, Brown V, Browning RS, Dawson L, Dooley KE, Gnanashanmugam D, Grinsztejn B, Hernandez-Diaz S, Jean-Philippe P, Kim P, Lyerly AD, Mirochnick M, Mofenson LM, Montepiedra G, Piper J, Sahin L, Savic R, Smith B, Spiegel H, Swaminathan S, Watts DH, White A. Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel. Clin Infect Dis. 2016 Mar 15; 62(6):761-9. PMID: 26658057.

    View in: PubMed

  40. Elliott JH, McMahon JH, Chang CC, Lee SA, Hartogensis W, Bumpus N, Savic RM, Roney J, Hoh R, Solomon A, Piatak M, Gorelick RJ, Lifson J, Bacchetti P, Deeks SG, Lewin SR. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose escalation study. Lancet HIV. 2015 Dec;2(12):e520-9. PMCID: PMC5108570.

    View in: PubMed

  41. Sundell K, Jagannathan P, Huang L, Bigira V, Kapisi J, Kakuru MM, Savic R, Kamya MR, Dorsey G, Aweeka F. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children. Malar J. 2015; 14(1):368. PMID: 26403465; PMCID: PMC4582734.

    View in: PubMed, PubMed Central

  42. Savic RM, Ruslami R, Hibma JE, Hesseling A, Ramachandran G, Ganiem AR, Swaminathan S, McIlleron H, Gupta A, Thakur K, van Crevel R, Aarnoutse R, Dooley KE. Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children. Clin Pharmacol Ther. 2015 Dec; 98(6):622-9. PMID: 26260983.

    View in: PubMed

  43. Via LE, Savic R, Weiner DM, Zimmerman MD, Prideaux B, Irwin SM, Lyon E, O'Brien P, Gopal P, Eum S, Lee M, Lanoix JP, Dutta NK, Shim T, Cho JS, Kim W, Karakousis PC, Lenaerts A, Nuermberger E, Barry CE, Dartois V. Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives. ACS Infect Dis. 2015 May 8; 1(5):203-214. PMID: 26086040.

    View in: PubMed

  44. Dooley KE, Savic RM, Park JG, Cramer Y, Hafner R, Hogg E, Janik J, Marzinke MA, Patterson K, Benson CA, Hovind L, Dorman SE, Haas DW. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrob Agents Chemother. 2015; 59(6):3399-405. PMID: 25824215; PMCID: PMC4432148.

    View in: PubMed, PubMed Central

  45. Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F. The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda. Pediatr Infect Dis J. 2015 Mar; 34(3):e63-70. PMID: 25742090; PMCID: PMC4351793 [Available on 03/01/16].

    View in: PubMed, PubMed Central

  46. Dorman SE, Savic R, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med. 2015 Feb 1; 191(3):333-43. PMID: 25489785.

    View in: PubMed

  47. Long-Boyle JR, Savic R, Yan S, Bartelink I, Musick L, French D, Law J, Horn B, Cowan MJ, Dvorak CC. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. Ther Drug Monit. 2015 Apr; 37(2):236-45. PMID: 25162216; PMCID: PMC4342323 [Available on 04/01/16].

    View in: PubMed, PubMed Central

  48. Sheffield JS, Siegel D, Mirochnick M, Heine RP, Nguyen C, Bergman KL, Savic RM, Long J, Dooley KE, Nesin M. Designing drug trials: considerations for pregnant women. Clin Infect Dis. 2014 Dec 15; 59 Suppl 7:S437-44. PMID: 25425722; PMCID: PMC4303056 [Available on 12/15/15].

    View in: PubMed, PubMed Central

  49. Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob Agents Chemother. 2014 Sep; 58(9):5245-52. PMID: 24957823; PMCID: PMC4135849.

    View in: PubMed, PubMed Central

  50. Vreeman RC, Nyandiko WM, Liechty EA, Busakhala N, Bartelink IH, Savic RM, Scanlon ML, Ayaya SO, Blaschke TF. Impact of adherence and anthropometric characteristics on nevirapine pharmacokinetics and exposure among HIV-infected Kenyan children. J Acquir Immune Defic Syndr. 2014 Nov 1; 67(3):277-86. PMID: 25140906.

    View in: PubMed

  51. Goswami S, Yee SW, Stocker S, Mosley JD, Kubo M, Castro R, Mefford JA, Wen C, Liang X, Witte J, Brett C, Maeda S, Simpson MD, Hedderson MM, Davis RL, Roden DM, Giacomini KM, Savic RM. Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 2014 Sep; 96(3):370-9. PMID: 24853734; PMCID: PMC4171106.

    View in: PubMed, PubMed Central

  52. Weiner M, Savic RM, Kenzie WR, Wing D, Peloquin CA, Engle M, Bliven E, Prihoda TJ, Gelfond JA, Scott NA, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterling TR, Villarino ME. Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection. J Pediatric Infect Dis Soc. 2014 Jun; 3(2):132-45. PMID: 26625366.

    View in: PubMed

  53. Savic RM, Lu Y, Bliven-Sizemore E, Weiner M, Nuermberger E, Burman W, Dorman SE, Dooley KE. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother. 2014 Jun; 58(6):3035-42. PMID: 24614383; PMCID: PMC4068478.

    View in: PubMed, PubMed Central

  54. Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, Charlebois E, Kamya M, Young SL, Gandhi M, Havlir D, Cohan D, Aweeka F. Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J Clin Pharmacol. 2014 Feb; 54(2):121-32. PMID: 24038035; PMCID: PMC3933454.

    View in: PubMed, PubMed Central

  55. Savic R, Cowan MJ, Dvorak CC, Pai SY, Pereira L, Bartelink IH, Boelens JJ, Bredius RG, Wynn RF, Cuvelier GD, Shaw PJ, Slatter MA, Long-Boyle J. Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1608-14. PMID: 24029650; PMCID: PMC3848313.

    View in: PubMed, PubMed Central

  56. Yee SW, Nguyen AN, Brown C, Savic R, Zhang Y, Castro RA, Cropp CD, Choi JH, Singh D, Tahara H, Stocker SL, Huang Y, Brett CM, Giacomini KM. Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8). J Pharm Sci. 2013 Sep; 102(9):3451-7. PMID: 23649425; PMCID: PMC4151246.

    View in: PubMed, PubMed Central

  57. Savic RM, Barrail-Tran A, Duval X, Nembot G, Panhard X, Descamps D, Verstuyft C, Vrijens B, Taburet AM, Goujard C, Mentré F. Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients. Clin Pharmacol Ther. 2012 Nov; 92(5):575-83. PMID: 23033116; PMCID: PMC3939416.

    View in: PubMed, PubMed Central

  58. Kang D, Bae KS, Houk BE, Savic R, Karlsson MO. Standard Error of Empirical Bayes Estimate in NONMEM® VI. Korean J Physiol Pharmacol. 2012 Apr; 16(2):97-106. PMID: 22563254; PMCID: PMC3339294.

    View in: PubMed, PubMed Central

  59. Crawford KW, Ripin DH, Levin AD, Campbell JR, Flexner C. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. Lancet Infect Dis. 2012 Jul; 12(7):550-60. PMID: 22742638.

    View in: PubMed

  60. Delattre M, Savic R, Miller R, Karlsson MO, Lavielle M. Analysis of exposure-response of CI-945 in patients with epilepsy: application of novel mixed hidden Markov modeling methodology. J Pharmacokinet Pharmacodyn. 2012 Jun; 39(3):263-71. PMID: 22544471.

    View in: PubMed

  61. Stocker SL, McLachlan AJ, Savic R, Kirkpatrick CM, Graham GG, Williams KM, Day RO. The pharmacokinetics of oxypurinol in people with gout. Br J Clin Pharmacol. 2012 Sep; 74(3):477-89. PMID: 22300439; PMCID: PMC3477349.

    View in: PubMed, PubMed Central

  62. Baverel PG, Savic R, Karlsson MO. Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models. J Pharmacokinet Pharmacodyn. 2011 Feb; 38(1):63-82. PMID: 21076858.

    View in: PubMed

  63. Savic R, Mentré F, Lavielle M. Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics. AAPS J. 2011 Mar; 13(1):44-53. PMID: 21063925; PMCID: PMC3032088.

    View in: PubMed, PubMed Central

2005–2010

  1. Savic R, Karlsson MO. Evaluation of an extended grid method for estimation using nonparametric distributions. AAPS J. 2009 Sep; 11(3):615-27. PMID: 19714472; PMCID: PMC2758131.

    View in: PubMed, PubMed Central

  2. Savic R, Lavielle M. Performance in population models for count data, part II: a new SAEM algorithm. J Pharmacokinet Pharmacodyn. 2009 Aug; 36(4):367-79. PMID: 19680795; PMCID: PMC2881036.

    View in: PubMed, PubMed Central

  3. Savic R, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009 Sep; 11(3):558-69. PMID: 19649712; PMCID: PMC2758126.

    View in: PubMed, PubMed Central

  4. Baverel PG, Savic R, Wilkins JJ, Karlsson MO. Evaluation of the nonparametric estimation method in NONMEM VI: application to real data. J Pharmacokinet Pharmacodyn. 2009 Aug; 36(4):297-315. PMID: 19572188.

    View in: PubMed

  5. Petersson KJ, Hanze E, Savic R, Karlsson MO. Semiparametric distributions with estimated shape parameters. Pharm Res. 2009 Sep; 26(9):2174-85. PMID: 19568693.

    View in: PubMed

  6. Carlsson KC, Savic R, Hooker AC, Karlsson MO. Modeling subpopulations with the $MIXTURE subroutine in NONMEM: finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making. AAPS J. 2009 Mar; 11(1):148-54. PMID: 19277871; PMCID: PMC2664892.

    View in: PubMed, PubMed Central

  7. Savic R, Kjellsson MC, Karlsson MO. Evaluation of the nonparametric estimation method in NONMEM VI. Eur J Pharm Sci. 2009 Apr 11; 37(1):27-35. PMID: 19159684.

    View in: PubMed

  8. Wilkins JJ, Savic R, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother. 2008 Jun; 52(6):2138-48. PMID: 18391026; PMCID: PMC2415769.

    View in: PubMed, PubMed Central

  9. Savic R, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007 Oct; 34(5):711-26. PMID: 17653836.

    View in: PubMed

  10. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007 Jul; 82(1):17-20. PMID: 17571070.

    View in: PubMed

  11. Hong EU, Savic R . Population Pharmacokinetic Analysis of the Oral Absorption Process of Tacrolimus in Healthy Volunteers . Kor J Clin Pharmacol Ther. 2007; 15(2):117-126.

  12. Osterberg O, Savic R, Karlsson MO, Simonsson US, Nørgaard JP, Walle JV, Agersø H. Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol. 2006 Oct; 46(10):1204-11. PMID: 16988210.

    View in: PubMed

  13. Lindemalm S, Savic R, Karlsson MO, Juliusson G, Liliemark J, Albertioni F. Application of population pharmacokinetics to cladribine. BMC Pharmacol. 2005; 5:4. PMID: 15757511; PMCID: PMC1079880.

    View in: PubMed, PubMed Central